Can Drostanolone Propionate be effectively combined with SARMs in the same cycle?

Yes — Drostanolone Propionate and SARMs operate through complementary but non-identical mechanisms, making the combination additive rather than redundant. SARMs provide tissue-selective anabolic signalling while Drostanolone Propionate delivers full androgen receptor agonism, DHT-mediated conditioning effects, and SHBG displacement. The result is a more complete androgenic environment than either agent produces independently, without requiring high total androgenic load.

Which specific SARMs pair most logically with Drostanolone Propionate 100mg/ml?

LGD-4033 and RAD-140 are the most structurally compatible SARMs for Drostanolone Propionate cycles because both support 8–12 week active durations matching the propionate ester's practical cycle length. Ostarine suits lower weekly Drostanolone Propionate doses (100–150mg) for a milder androgenic overlay, while RAD-140's stronger anabolic drive pairs productively with 200–300mg weekly Drostanolone Propionate for experienced athletes pursuing hardness and definition simultaneously.

What monitoring should be in place when running a SARM and Drostanolone Propionate stack?

Lipid panels — specifically LDL and HDL fractions — require monitoring at baseline and mid-cycle because both SARMs and Drostanolone Propionate suppress HDL through different pathways, making the combined impact greater than either alone. Haematocrit should also be checked if the SARM has mild erythropoietic activity. Liver enzymes are a lower concern with injectable Drostanolone Propionate compared to oral androgens, but remain a standard mid-cycle data point when any SARM is co-administered.

How does the 100mg/ml concentration compare to higher-strength Drostanolone Propionate products when calculating SARM stack doses?

The 100mg/ml concentration is the lowest available in this product group, providing the finest dose increments — 10mg per 0.1ml graduation — which is directly useful in SARM stacks where the androgenic contribution must be adjusted precisely without overshooting total weekly androgenic load. Higher-concentration formats reduce injection volume but make sub-50mg adjustments harder to measure accurately, a relevant trade-off when the SARM already contributes receptor activity.

After opening the 10ml vial, how should it be stored and how long does it remain viable?

Once broached, the multi-dose vial should be stored at controlled room temperature (15–25°C) away from direct light, in a clean, dry location. Multi-dose vials with benzyl alcohol or benzyl benzoate preservative systems remain sterile for up to 28 days after first puncture when handled with a fresh needle each draw. Refrigeration is acceptable but not mandatory; always allow the oil to return to room temperature before drawing to reduce injection-site discomfort and ensure the solution flows cleanly. (2) angle_used

Purity Tested

Rossiaz Lab

Drostanolone Propionate 100mg/ml 10ml Vial by Rossiaz Lab

Name: Drostanolone Propionate 100mg/ml 10ml Vial by Rossiaz Lab
Brand: Rossiaz Lab
SKU: INJ-DROP-ROS-100-023
Price: 50.00 EUR
Availability: InStock

Hilma Biocare Drostanolone Propionate 100mg/ml is a short-ester injectable androgen formulated at a clinically practical concentration, distinguished by its predictable pharmacokinetic profile — characterised by a half-life of approximately 2–3 days that governs injection scheduling and steady-state accumulation across the cycle. Because the propionate ester dictates such a defined release window, serum concentration behaviour is measurable, repeatable, and directly linked to dosing intervals rather than to subjective response. Batch-release documentation — including HPLC-confirmed potency and LAL endotoxin data — is supplied lot-specific, with each 10ml multi-dose vial manufactured under EU GMP-compliant aseptic conditions.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Fills the androgenic signalling gap that tissue-selective SARMs intentionally leave
SHBG displacement elevates free androgen fractions across the entire stack without dose escalation
2α-methyl backbone modification extends receptor occupancy per injection within the propionate release window
100mg/ml concentration allows 10mg incremental dose adjustments — the finest granularity in this product range
10ml multi-dose vial accommodates a full SARM-compatible 10-week every-other-day protocol in a single container
Batch-specific HPLC and LAL CoA confirms potency and parenteral safety simultaneously
Propionate ester clears rapidly post-cycle, allowing SARM-only continuation or prompt PCT without extended washout

Phase	Drostanolone Propionate Dose	Note
SARM Introduction (Weeks 1–2)	100mg/week (EOD injections of ~33mg)	Low androgenic overlay allows SARM baseline response to establish; 100mg/ml concentration makes sub-50mg doses measurable
Main Stack Phase (Weeks 3–8)	200–300mg/week (EOD injections of 67–100mg)	Peak androgenic complement to LGD-4033 or RAD-140 SARM dose; monitor lipids at week 4
Pre-Cycle Exit (Weeks 9–10)	100–150mg/week (taper)	Allows propionate levels to decline before PCT or SARM-only continuation; final injection 3–4 days before transition
PCT / Transition	Discontinued	Propionate clears within approximately 5–7 days; SARM PCT or standard HPTA recovery protocol as appropriate

Drostanolone Propionate as the Androgen Anchor in SARM Hybrid Protocols

Rossiaz Lab Drostanolone Propionate 100mg/ml functions as a full agonist androgen receptor activator designed to complement the tissue-selective partial agonism characteristic of SARMs, creating a pharmacological pairing where each modality addresses a different aspect of androgen signalling. SARMs — compounds such as LGD-4033, RAD-140, or Ostarine — achieve anabolic effects through selective receptor activation in muscle and bone while producing limited androgenic signal in other tissues. Drostanolone Propionate fills the androgenic gap that selective modulators intentionally leave, providing classical DHT-mediated effects including neuromuscular tone, skin-surface conditioning, and SHBG displacement that SARMs cannot replicate through their partial agonist mechanism.

SARMs generate anabolic signalling in skeletal muscle, but the androgenic overlay from Drostanolone Propionate completes the hormonal environment necessary for competition-level conditioning. Compared to running SARMs as a standalone protocol, adding Drostanolone Propionate at 100–200mg per week produces measurably greater hardness and vascularity outcomes without substantially increasing total weekly androgenic load — because the SHBG-displacing action of Drostanolone Propionate elevates free androgen fractions across the stack. The 2α-methyl modification on the drostanolone backbone resists enzymatic inactivation in muscle tissue, extending meaningful receptor occupancy per dose within the short propionate release window.

Dosing Logic for SARM-Drostanolone Propionate Combination Cycles

The 100mg/ml concentration is the most arithmetically flexible format for SARM hybrid cycles, where total weekly androgen load requires careful management alongside the SARM dose. At 0.5ml per injection, an athlete delivers exactly 50mg of Drostanolone Propionate, making every-other-day injection schedules simple to construct alongside a daily oral or sublingual SARM regimen. A standard HPLC-verified potency result — documented on the lot-specific CoA — confirms that 0.5ml draws 50mg rather than an unquantified estimate, which matters when the SARM component is already contributing to receptor occupancy.

LGD-4033 and RAD-140 are the most frequently paired SARMs in Drostanolone Propionate combination cycles because both share an 8–12 week active use window compatible with a propionate-ester injectable. Ostarine-based stacks favour lower Drostanolone Propionate doses (100–150mg weekly) given Ostarine's comparatively mild androgenic stimulus, whereas RAD-140 stacks can tolerate 200–300mg weekly Drostanolone Propionate without compounding androgenic side-effect risk significantly.

Purity Verification Supporting Multi-Compound Protocols

Rossiaz Lab subjects every Drostanolone Propionate 100mg/ml batch to reversed-phase HPLC content assay and LAL (Limulus Amebocyte Lysate) endotoxin quantification under GMP-aligned environmental controls. The LAL endotoxin test result sits on the same lot-numbered Certificate of Analysis as the HPLC potency figure, giving practitioners a single document covering both safety and concentration integrity — a critical assurance when combining multiple parenteral administrations with an oral or sublingual SARM across a 10–12 week cycle.

Usage

Confirm your SARM selection and weekly dose before calculating Drostanolone Propionate contribution — total androgenic load from both agents combined informs your starting injection volume.
Inspect the vial's HPLC Certificate of Analysis to verify lot-specific potency before drawing the first dose; the 100mg/ml figure should match the CoA concentration result.
Draw the calculated volume using a fresh, sterile needle — for doses of 50mg or below, a 1ml luer-lock syringe provides sufficient graduation precision at 100mg/ml.
Administer by intramuscular injection into the glute, quad, or lateral deltoid on an every-other-day schedule, alternating sites to minimise localised irritation across a 10-week cycle.
Log each injection date, dose, and injection site alongside your SARM dose; this record supports mid-cycle lipid panel interpretation and end-of-cycle dose tapering decisions.
Reseal the vial with the original rubber stopper after each draw, store at room temperature away from light, and discard after 28 days from first puncture regardless of remaining volume.

Warnings

Contraindications: Drostanolone Propionate is contraindicated in individuals with androgen-sensitive prostate pathology, elevated haematocrit (>54%), or a documented hypersensitivity to DHT-derived androgens. Women of childbearing age should not use this compound due to virilisation risk. The propionate ester's oil-based vehicle is unsuitable for individuals with known hypersensitivity to sesame or benzyl alcohol excipients.

Side Effects: Androgenic effects — accelerated scalp hair recession in genetically predisposed individuals, increased sebum production, and potential acne — are the primary concerns. HDL suppression occurs through androgen receptor-mediated pathways; when co-administered with a SARM that also reduces HDL, the combined lipid impact requires active monitoring. Haematocrit elevation is possible, particularly if the stacked SARM has mild erythropoietic properties.

Monitoring: Lipid panel (LDL, HDL, total cholesterol, triglycerides) at baseline, week 4–5, and post-cycle. Full blood count including haematocrit if combining with RAD-140 or other anabolic SARMs. Blood pressure should be self-monitored weekly given the androgenic vascularity-promoting effects of the stack. Liver enzymes are a lower priority with injectable Drostanolone Propionate but remain part of responsible mid-cycle bloodwork when any additional agent is co-administered.

PCT: Post-cycle therapy depends on whether the stack includes exogenous testosterone. Drostanolone Propionate alone does not fully suppress the HPG axis but reduces endogenous testosterone output; if paired with a suppressive SARM such as RAD-140 or LGD-4033, HPTA recovery support with a SERM (e.g., Nolvadex 20–40mg/day for 4–6 weeks) is recommended. PCT initiation should begin approximately 5–7 days after the final propionate injection to account for ester clearance.

Frequently asked questions

Can Drostanolone Propionate be effectively combined with SARMs in the same cycle?: Yes — Drostanolone Propionate and SARMs operate through complementary but non-identical mechanisms, making the combination additive rather than redundant. SARMs provide tissue-selective anabolic signalling while Drostanolone Propionate delivers full androgen receptor agonism, DHT-mediated conditioning effects, and SHBG displacement. The result is a more complete androgenic environment than either agent produces independently, without requiring high total androgenic load.
Which specific SARMs pair most logically with Drostanolone Propionate 100mg/ml?: LGD-4033 and RAD-140 are the most structurally compatible SARMs for Drostanolone Propionate cycles because both support 8–12 week active durations matching the propionate ester's practical cycle length. Ostarine suits lower weekly Drostanolone Propionate doses (100–150mg) for a milder androgenic overlay, while RAD-140's stronger anabolic drive pairs productively with 200–300mg weekly Drostanolone Propionate for experienced athletes pursuing hardness and definition simultaneously.
What monitoring should be in place when running a SARM and Drostanolone Propionate stack?: Lipid panels — specifically LDL and HDL fractions — require monitoring at baseline and mid-cycle because both SARMs and Drostanolone Propionate suppress HDL through different pathways, making the combined impact greater than either alone. Haematocrit should also be checked if the SARM has mild erythropoietic activity. Liver enzymes are a lower concern with injectable Drostanolone Propionate compared to oral androgens, but remain a standard mid-cycle data point when any SARM is co-administered.
How does the 100mg/ml concentration compare to higher-strength Drostanolone Propionate products when calculating SARM stack doses?: The 100mg/ml concentration is the lowest available in this product group, providing the finest dose increments — 10mg per 0.1ml graduation — which is directly useful in SARM stacks where the androgenic contribution must be adjusted precisely without overshooting total weekly androgenic load. Higher-concentration formats reduce injection volume but make sub-50mg adjustments harder to measure accurately, a relevant trade-off when the SARM already contributes receptor activity.
After opening the 10ml vial, how should it be stored and how long does it remain viable?: Once broached, the multi-dose vial should be stored at controlled room temperature (15–25°C) away from direct light, in a clean, dry location. Multi-dose vials with benzyl alcohol or benzyl benzoate preservative systems remain sterile for up to 28 days after first puncture when handled with a fresh needle each draw. Refrigeration is acceptable but not mandatory; always allow the oil to return to room temperature before drawing to reduce injection-site discomfort and ensure the solution flows cleanly. (2) angle_used

Manufacturer

Rossiaz Lab's approach to analytical quality control is structured around one operational principle: every data point on the Certificate of Analysis must be traceable to the specific production lot it covers, not to a representative batch or periodic audit sample. For Drostanolone Propionate 100mg/ml, this means reversed-phase HPLC potency quantification is executed at the individual lot level — generating a concentration figure tied to the exact vials being released rather than interpolated from a periodic standard. The LAL (Limulus Amebocyte Lysate) endotoxin assay runs in parallel as a mandatory pre-release gate; no lot proceeds to distribution until both the HPLC potency result and the LAL endotoxin value are documented and within specification on the same CoA. This dual-gate release architecture is applied uniformly across the injectable portfolio under GMP-aligned environmental controls, ensuring that the parenteral safety standard for a multi-draw vial used across a 10-week SARM combination cycle is equivalent to that applied to any single-use format in the range.

Product details

Brand	Rossiaz Lab
Active ingredient	drostanolone propionate
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROP-ROS-100-023

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00